Recordati Industria Chimica e Farmaceutica SpA
MIL:REC

Watchlist Manager
Recordati Industria Chimica e Farmaceutica SpA Logo
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Watchlist
Price: 48.28 EUR -0.54% Market Closed
Market Cap: 10.1B EUR

Recordati Industria Chimica e Farmaceutica SpA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Recordati Industria Chimica e Farmaceutica SpA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Cash from Operating Activities
€574.9m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Newron Pharmaceuticals SpA
SIX:NWRN
Cash from Operating Activities
-€17.6m
CAGR 3-Years
-15%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Recordati Industria Chimica e Farmaceutica SpA
Glance View

Nestled within the vibrant landscape of the Italian pharmaceutical industry, Recordati Industria Chimica e Farmaceutica SpA has carved a distinct identity over its nearly century-long journey. Founded in 1926 by Giovanni Recordati, the company has evolved from a small chemical laboratory into one of Europe's prominent players in pharmaceuticals. The heart of Recordati's operations lies in its robust portfolio, which spans pharmaceuticals, rare disease treatments, and consumer health products. With a commitment to innovation and diligent R&D efforts, Recordati continuously develops both proprietary drugs and generic medicines, ensuring a diverse revenue stream. Aiming to address crucial health challenges, the company has strategically expanded its rare disease segment, exploring niche markets with high unmet medical needs. Recordati's business model is a sophisticated blend of internal development, strategic acquisitions, and partnerships. The company's success largely hinges on its ability to identify and integrate complementary businesses, enhancing its global footprint. Through a network covering Western Europe, Central and Eastern Europe, as well as North America and emerging markets, Recordati not only distributes its own line of medications but also collaborates with other pharmaceutical entities to commercialize their products. This strategic expansion, coupled with a proactive approach to fostering market-specific adaptations, supports a steady flow of revenue. Revenue sustainability is further bolstered by a responsive supply chain and targeted marketing strategies that strengthen Recordati's competitive stance in the pharmaceutical sector worldwide.

REC Intrinsic Value
62.38 EUR
Undervaluation 23%
Intrinsic Value
Price

See Also

What is Recordati Industria Chimica e Farmaceutica SpA's Cash from Operating Activities?
Cash from Operating Activities
574.9m EUR

Based on the financial report for Jun 30, 2025, Recordati Industria Chimica e Farmaceutica SpA's Cash from Operating Activities amounts to 574.9m EUR.

What is Recordati Industria Chimica e Farmaceutica SpA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
10%

Over the last year, the Cash from Operating Activities growth was 20%. The average annual Cash from Operating Activities growth rates for Recordati Industria Chimica e Farmaceutica SpA have been 4% over the past three years , 8% over the past five years , and 10% over the past ten years .

Back to Top